Michael Kaufman (file photo)

Karyopharm spot­lights PhI­II re­sults af­ter con­tro­ver­sial FDA ap­proval

There are moun­tain ranges with less jagged curves than Karyopharm’s stock $KP­TI.

Over the last year, the biotech has risen and cratered and risen again as a de­bate over whether its lead drug is safe — or even works — played out in pub­lic FDA re­views and ad­vi­so­ry com­mit­tee hear­ings. But af­ter a skep­ti­cal in­ter­nal re­view from the agency not­ed pre­vi­ous­ly undis­closed tri­al deaths and a sol­id ma­jor­i­ty of out­side ad­vi­sors vot­ed to re­ject the drug, Karyopharm emerged in Ju­ly with a sur­prise ac­cel­er­at­ed ap­proval for se­linex­or, now called Xpovio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.